Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players
Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells,...
Uložené v:
| Vydané v: | Oncogene Ročník 38; číslo 34; s. 6172 - 6183 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
Nature Publishing Group UK
01.08.2019
Nature Publishing Group |
| Predmet: | |
| ISSN: | 0950-9232, 1476-5594, 1476-5594 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component
telomerase reverse transcriptase (TERT)
gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the
TERT
gene and promoter were cloned, the derepression of the
TERT
gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the
TERT
gene. In this review article, we summarize critical mechanisms activating
TERT
transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the
TERT
locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well. |
|---|---|
| AbstractList | Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well. Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well. Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well.Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well. |
| Audience | Academic |
| Author | Xu, Dawei Larsson, Catharina Yuan, Xiaotian |
| Author_xml | – sequence: 1 givenname: Xiaotian surname: Yuan fullname: Yuan, Xiaotian email: Xiaotian.Yan@ki.se organization: School of Medicine, Shandong University, Department of Medicine, Center for Molecular Medicine (CMM) and Bioclinicum, Karolinska Institutet and Karolinska University Hospital Solna – sequence: 2 givenname: Catharina surname: Larsson fullname: Larsson, Catharina organization: Department of Oncology-Pathology and Bioclinicum, Karolinska Institutet and Karolinska University Hospital Solna – sequence: 3 givenname: Dawei surname: Xu fullname: Xu, Dawei email: Dawei.Xu@ki.se organization: Department of Medicine, Center for Molecular Medicine (CMM) and Bioclinicum, Karolinska Institutet and Karolinska University Hospital Solna |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31285550$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:141677504$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNp9kk1v1DAQhiNURLeFH8AFWeLSS4o_4jjmgFRV5UMqQkLL2fLak12XxF7spNVe-O04u0vLVoB8sDXzvDMe-z0pjnzwUBQvCT4nmDVvUkVY05SYyBI3gpbySTEjlahLzmV1VMyw5LiUlNHj4iSlG4yxkJg-K44ZoQ3nHM-Kn5_BrLR3qU9o9BZit3F-iYYVIG0Gd6sHFzwKLZpffZ2jIWqfTHTrbVR7iwboQg9Rpz3vhg1yHq3GXntktDcQ36LQ2SkbYtpqPNyhdac3ENPz4mmruwQv9vtp8e391fzyY3n95cOny4vr0tQVGUrLWWUlsQvaWIm5ZJLUmtW4NiCBWGYqYRljbWsY0Q1nlNXVgtN2UbetkAyz06Lc1U13sB4Xah1dr-NGBe3UPvQ9n0BVouFUZP7djs-ZHqwBn0fvDmSHGe9WahluVS14vpbMBc72BWL4MUIaVO-Sga7THsKYFKW84gRTRjL6-hF6E8bo83NkSoiKyIryB2qpO1DOtyH3NVNRdcGlwKIRnGbq_C9UXhZ6Z7J7WpfjB4JXfw56P-Fvh2SA7AATQ0oR2nuEYDW5UO1cqLIL1eRCNQ0vHmmMG7ZOyrdx3X-VdP9PuYtfQnx4i3-LfgEjhvFe |
| CitedBy_id | crossref_primary_10_1136_bmjopen_2020_044055 crossref_primary_10_1016_j_omton_2025_200936 crossref_primary_10_1016_j_canlet_2020_07_003 crossref_primary_10_1093_nar_gkab853 crossref_primary_10_3389_fcell_2025_1592135 crossref_primary_10_1007_s00262_025_03971_y crossref_primary_10_24171_j_phrp_2021_0207 crossref_primary_10_1111_liv_16202 crossref_primary_10_1016_j_synbio_2025_09_016 crossref_primary_10_1007_s12672_023_00760_w crossref_primary_10_1007_s11033_025_10251_6 crossref_primary_10_1111_exd_14518 crossref_primary_10_3389_fmed_2022_888850 crossref_primary_10_3389_fmolb_2021_751842 crossref_primary_10_1016_j_jtcvs_2022_03_038 crossref_primary_10_3389_fonc_2022_1030590 crossref_primary_10_1016_j_jid_2022_11_016 crossref_primary_10_1084_jem_20240435 crossref_primary_10_3390_cancers13092042 crossref_primary_10_1158_0008_5472_CAN_25_0482 crossref_primary_10_1016_j_jid_2022_03_031 crossref_primary_10_3390_ijms222312705 crossref_primary_10_3389_fgene_2021_662464 crossref_primary_10_3390_biomedicines12020378 crossref_primary_10_1016_j_ygyno_2023_10_007 crossref_primary_10_3389_fonc_2023_1180099 crossref_primary_10_1038_s41598_025_87545_z crossref_primary_10_1186_s13104_023_06566_x crossref_primary_10_1371_journal_pgen_1009201 crossref_primary_10_3390_ph17091136 crossref_primary_10_3390_pharmaceutics14091861 crossref_primary_10_3390_cancers17060954 crossref_primary_10_3390_cancers13133340 crossref_primary_10_3390_ijms21176034 crossref_primary_10_1007_s42764_021_00052_z crossref_primary_10_3390_biom10101450 crossref_primary_10_1073_pnas_2022779118 crossref_primary_10_3390_ijms26146765 crossref_primary_10_1016_j_ctarc_2024_100837 crossref_primary_10_3389_fmicb_2023_1128433 crossref_primary_10_3390_cancers12061597 crossref_primary_10_3390_cancers14071655 crossref_primary_10_1016_j_gene_2023_147460 crossref_primary_10_1002_ctm2_109 crossref_primary_10_1016_j_jmoldx_2020_11_003 crossref_primary_10_3390_genes12081188 crossref_primary_10_1038_s41379_020_00716_3 crossref_primary_10_3390_cancers16111995 crossref_primary_10_3390_cells9030749 crossref_primary_10_1080_26896583_2023_2271822 crossref_primary_10_1016_j_humgen_2023_201254 crossref_primary_10_1016_j_legalmed_2023_102270 crossref_primary_10_1038_s41467_020_19314_7 crossref_primary_10_1016_j_jbc_2024_107392 crossref_primary_10_3390_biology12081126 crossref_primary_10_1016_j_anndiagpath_2024_152290 crossref_primary_10_1007_s00109_024_02467_z crossref_primary_10_1073_pnas_2008772118 crossref_primary_10_3390_ijms20133338 crossref_primary_10_2147_JHC_S307962 crossref_primary_10_4062_biomolther_2025_040 crossref_primary_10_1007_s12010_022_04000_9 crossref_primary_10_1016_j_yexcr_2019_111643 crossref_primary_10_3390_jcm13072150 crossref_primary_10_1016_j_mad_2025_112026 crossref_primary_10_1016_j_molcel_2025_05_026 crossref_primary_10_1002_cam4_6784 crossref_primary_10_1080_07391102_2024_2310212 crossref_primary_10_1186_s13578_021_00675_5 crossref_primary_10_1016_j_pharmthera_2020_107722 crossref_primary_10_1002_ctm2_640 crossref_primary_10_1111_cas_15256 crossref_primary_10_1038_s41467_022_34383_6 crossref_primary_10_1186_s12967_020_02647_8 crossref_primary_10_3390_ijms22157992 crossref_primary_10_3390_diagnostics15091171 crossref_primary_10_3389_fonc_2024_1325345 crossref_primary_10_1016_j_lfs_2025_123381 crossref_primary_10_1128_jvi_02061_21 crossref_primary_10_1186_s12885_024_13125_5 crossref_primary_10_3390_vaccines8020318 crossref_primary_10_1002_gcc_22955 crossref_primary_10_3390_cancers12102953 crossref_primary_10_1016_j_biopha_2022_114193 crossref_primary_10_1016_j_heliyon_2023_e23519 crossref_primary_10_1002_cjp2_338 crossref_primary_10_1038_s41568_023_00565_7 crossref_primary_10_1186_s40478_020_01022_4 crossref_primary_10_3389_fonc_2021_795242 crossref_primary_10_1038_s41379_022_01138_z crossref_primary_10_1007_s13258_024_01610_x crossref_primary_10_1007_s00438_024_02207_5 crossref_primary_10_3389_fimmu_2020_589929 crossref_primary_10_1038_s41598_020_77648_0 crossref_primary_10_3390_cells12141860 crossref_primary_10_1002_fsn3_4555 crossref_primary_10_1038_s41419_020_03048_x crossref_primary_10_3390_ijms26030993 crossref_primary_10_3389_fonc_2022_798018 crossref_primary_10_1016_j_mrfmmm_2025_111901 crossref_primary_10_1007_s12672_025_02311_x crossref_primary_10_1007_s12029_020_00565_y crossref_primary_10_3390_cancers14030808 crossref_primary_10_1111_bpa_13107 crossref_primary_10_1158_1078_0432_CCR_24_3277 crossref_primary_10_1002_ctm2_1111 crossref_primary_10_3390_cancers12082133 crossref_primary_10_1038_s41419_025_07935_z crossref_primary_10_1097_XCE_0000000000000232 crossref_primary_10_1186_s12885_024_13421_0 crossref_primary_10_3390_cancers12061679 crossref_primary_10_3390_biomedicines11030691 crossref_primary_10_1093_nsr_nwaa306 crossref_primary_10_3390_life11121405 crossref_primary_10_1016_j_molstruc_2022_134346 crossref_primary_10_1093_nar_gkae914 crossref_primary_10_1007_s40291_021_00572_0 crossref_primary_10_1097_JCMA_0000000000000535 crossref_primary_10_3390_ijms22126381 crossref_primary_10_1002_ijc_33954 crossref_primary_10_1007_s00438_024_02206_6 crossref_primary_10_1007_s13577_023_00925_3 crossref_primary_10_1002_jmv_29665 crossref_primary_10_1111_his_14024 crossref_primary_10_1371_journal_pone_0240807 crossref_primary_10_3389_fendo_2021_643151 crossref_primary_10_1111_jop_13364 crossref_primary_10_3390_cancers14112711 crossref_primary_10_1016_j_bbrc_2020_04_058 crossref_primary_10_1038_s41467_024_50233_z crossref_primary_10_1016_j_gde_2022_101919 crossref_primary_10_1186_s13293_023_00526_7 crossref_primary_10_1002_1878_0261_70048 crossref_primary_10_1016_j_lfs_2020_118387 crossref_primary_10_1038_s41420_024_02135_8 crossref_primary_10_1016_j_jmb_2025_168951 crossref_primary_10_3390_ijms23094536 crossref_primary_10_1016_j_mrgentox_2023_503670 crossref_primary_10_1007_s10266_025_01080_x crossref_primary_10_1007_s40944_024_00858_1 crossref_primary_10_1016_j_urolonc_2021_01_022 crossref_primary_10_1038_s41598_023_45716_w crossref_primary_10_1007_s11357_023_00794_6 crossref_primary_10_1007_s00432_022_04372_9 crossref_primary_10_1016_j_ymeth_2025_05_001 crossref_primary_10_26779_2786_832X_2023_6_23 crossref_primary_10_1097_HEP_0000000000000667 crossref_primary_10_1016_j_biopha_2025_118215 crossref_primary_10_1016_j_urolonc_2024_06_024 crossref_primary_10_3390_biomedicines9101335 crossref_primary_10_1038_s41598_023_44844_7 crossref_primary_10_3389_fbioe_2022_847433 crossref_primary_10_3390_ijms252413404 crossref_primary_10_1186_s13148_025_01897_x crossref_primary_10_1016_j_mad_2022_111756 crossref_primary_10_1038_s41598_022_07691_6 crossref_primary_10_3389_fendo_2020_00485 crossref_primary_10_3389_fonc_2021_619351 crossref_primary_10_3390_cancers16040735 crossref_primary_10_3390_biomedicines13020281 crossref_primary_10_3390_cancers12061625 crossref_primary_10_3390_biomedicines10123202 crossref_primary_10_7554_eLife_66198 crossref_primary_10_1007_s00705_025_06335_0 crossref_primary_10_1007_s12022_020_09635_0 crossref_primary_10_1007_s00018_024_05415_9 crossref_primary_10_1016_j_fitote_2020_104771 crossref_primary_10_1155_2020_6946037 crossref_primary_10_3389_fimmu_2023_1208223 crossref_primary_10_3390_ijms24043182 crossref_primary_10_3390_pharmaceutics17070826 crossref_primary_10_1038_s41379_022_01122_7 crossref_primary_10_3390_biology11010141 crossref_primary_10_3390_molecules25204641 crossref_primary_10_3390_antib11030049 crossref_primary_10_3389_fonc_2025_1542930 crossref_primary_10_1016_j_bbcan_2024_189243 crossref_primary_10_15252_embj_2020106336 crossref_primary_10_1186_s13073_022_01029_7 crossref_primary_10_1016_j_jormas_2025_102433 crossref_primary_10_1097_DAD_0000000000002366 crossref_primary_10_3390_ijms25158340 crossref_primary_10_1038_s41580_020_0234_z crossref_primary_10_3389_fimmu_2025_1585647 crossref_primary_10_1016_j_virol_2024_110273 crossref_primary_10_1080_14728222_2022_2147062 crossref_primary_10_3892_ol_2020_11770 crossref_primary_10_1182_bloodadvances_2019000167 crossref_primary_10_1186_s12885_023_10979_z crossref_primary_10_1007_s00439_024_02707_9 crossref_primary_10_1016_j_isci_2025_113159 crossref_primary_10_1038_s41379_021_00874_y crossref_primary_10_3892_ijo_2021_5271 crossref_primary_10_12688_f1000research_132031_2 crossref_primary_10_3389_fendo_2020_00269 crossref_primary_10_12688_f1000research_132031_1 crossref_primary_10_3390_molecules26216603 crossref_primary_10_3389_fphar_2021_631835 crossref_primary_10_3390_genes14061200 crossref_primary_10_1007_s12020_020_02524_w crossref_primary_10_1016_j_biopha_2022_112796 crossref_primary_10_1096_fj_201902147R crossref_primary_10_1073_pnas_2102423118 crossref_primary_10_3389_fimmu_2022_1071390 crossref_primary_10_1002_ijc_33750 crossref_primary_10_1016_j_bcp_2024_116277 crossref_primary_10_1158_1541_7786_MCR_19_1244 crossref_primary_10_1186_s12935_024_03459_2 crossref_primary_10_3389_fonc_2022_919351 crossref_primary_10_3390_ijms25115660 crossref_primary_10_1038_s41598_025_08986_0 crossref_primary_10_3390_cancers14020276 crossref_primary_10_1016_j_prp_2022_153892 crossref_primary_10_3389_fonc_2021_642719 crossref_primary_10_1016_j_bbrc_2022_11_068 crossref_primary_10_1038_s41388_021_01894_3 crossref_primary_10_1007_s12026_024_09504_6 crossref_primary_10_1186_s13000_025_01643_0 crossref_primary_10_3390_cells11050877 crossref_primary_10_1186_s12920_022_01175_2 crossref_primary_10_3390_ijms26094175 crossref_primary_10_1016_S2213_2600_24_00124_3 crossref_primary_10_3390_biomedicines9121773 crossref_primary_10_1002_lio2_654 crossref_primary_10_1038_s43018_021_00250_4 crossref_primary_10_1093_carcin_bgae024 crossref_primary_10_1016_j_jep_2025_120073 crossref_primary_10_3892_or_2021_8133 crossref_primary_10_1111_and_13976 crossref_primary_10_1038_s41467_024_51336_3 crossref_primary_10_3390_cells10020208 crossref_primary_10_1016_j_canlet_2019_11_017 crossref_primary_10_3389_fonc_2023_1133902 crossref_primary_10_3390_cancers16030546 crossref_primary_10_1016_j_canlet_2024_217408 crossref_primary_10_3390_biom13091308 crossref_primary_10_1080_10641955_2020_1869248 crossref_primary_10_1093_pnasnexus_pgad211 crossref_primary_10_1038_s41418_019_0466_7 crossref_primary_10_3390_life13061382 crossref_primary_10_2174_1381612826666200403131514 crossref_primary_10_3389_fonc_2023_1277453 crossref_primary_10_1016_j_ctarc_2021_100323 crossref_primary_10_3390_cancers12040949 crossref_primary_10_1111_1440_1681_13223 crossref_primary_10_1177_18758592241306263 crossref_primary_10_3390_cancers14215257 crossref_primary_10_3390_life15010126 crossref_primary_10_52586_S559 crossref_primary_10_24287_1726_1708_2021_20_4_178_184 crossref_primary_10_3389_fgene_2024_1401100 crossref_primary_10_1007_s13402_023_00886_7 crossref_primary_10_1007_s00018_023_04713_y crossref_primary_10_1186_s13059_022_02751_6 crossref_primary_10_3390_biomedicines10030728 crossref_primary_10_3390_nu17121983 crossref_primary_10_1007_s44169_023_00042_0 crossref_primary_10_1016_j_clgc_2021_02_002 crossref_primary_10_12677_WJCR_2022_122009 crossref_primary_10_3389_fimmu_2023_1218987 crossref_primary_10_3390_ijms251910405 crossref_primary_10_3390_jpm11080823 crossref_primary_10_3389_fcell_2023_1286683 crossref_primary_10_1186_s42047_024_00157_1 crossref_primary_10_3390_cancers14133108 crossref_primary_10_1002_path_6351 crossref_primary_10_1186_s12967_020_02347_3 crossref_primary_10_3390_ijms25158542 crossref_primary_10_1038_s41598_022_22282_1 crossref_primary_10_1007_s00018_021_04113_0 crossref_primary_10_1038_s42003_025_08695_4 crossref_primary_10_1080_09553002_2021_1956010 crossref_primary_10_3390_cancers12071889 crossref_primary_10_4103_JOC_JOC_26_21 crossref_primary_10_1016_j_gde_2020_01_002 crossref_primary_10_1134_S000629792314002X crossref_primary_10_1134_S0026893321030055 crossref_primary_10_1038_s41467_023_44360_2 crossref_primary_10_1038_s41598_021_03554_8 crossref_primary_10_1016_j_bcp_2024_116193 crossref_primary_10_1073_pnas_2121499119 crossref_primary_10_1089_crispr_2022_0032 crossref_primary_10_1002_adbi_202000030 crossref_primary_10_1007_s40135_025_00334_9 crossref_primary_10_3389_fonc_2021_747592 crossref_primary_10_3390_ijms22041950 crossref_primary_10_1073_pnas_2105171119 crossref_primary_10_1126_science_abg5601 crossref_primary_10_1038_s41598_021_94711_6 crossref_primary_10_1111_bpa_12892 crossref_primary_10_3390_cancers14061385 crossref_primary_10_1038_s41388_020_1291_7 |
| Cites_doi | 10.1073/pnas.0503095102 10.2174/1381612820666140630095606 10.1016/j.ccr.2014.07.014 10.1093/nar/gkw549 10.1158/0008-5472.CAN-16-1887 10.1038/ng.3389 10.1016/S1470-2045(13)70110-4 10.1016/j.cell.2011.02.013 10.1002/cbf.3051 10.1172/JCI91161 10.1530/ERC-17-0306 10.1038/s41467-018-07552-9 10.1038/nature08137 10.18632/oncotarget.15498 10.1016/j.cell.2018.02.020 10.1093/jnci/djp031 10.1038/onc.2012.441 10.1111/acel.12161 10.1038/onc.2013.446 10.1038/ng.2295 10.3390/ijms16011192 10.1126/science.1229259 10.1016/j.eururo.2013.08.057 10.1038/22780 10.1158/0008-5472.CAN-08-1323 10.1038/ng.3438 10.1038/s41388-018-0483-x 10.1172/JCI14064 10.1007/s00277-016-2787-7 10.1136/gutjnl-2015-309322 10.3390/genes7070038 10.1016/j.canlet.2018.07.013 10.18632/oncotarget.2491 10.1002/gcc.20698 10.1016/j.ccell.2018.08.003 10.1016/j.leukres.2012.10.009 10.1634/theoncologist.2014-0391 10.1038/sj.neo.7900114 10.1128/MCB.26.1.230-237.2006 10.1093/jnci/djm269 10.1016/j.tig.2014.07.006 10.1634/theoncologist.2017-0064 10.1056/NEJMp1508811 10.1136/jclinpath-2018-205132 10.1158/1078-0432.CCR-05-0099 10.1200/JCO.2014.55.5094 10.1101/gad.1214704 10.1158/1541-7786.MCR-16-0003 10.1096/fj.13-230904 10.1038/ng.3781 10.1038/nm0395-249 10.1002/hed.24728 10.1158/0008-5472.CAN-06-4126 10.1172/JCI121303 10.1038/sj.onc.1206492 10.18632/oncotarget.4295 10.1111/j.1474-9726.2011.00718.x 10.1016/j.canlet.2007.10.018 10.1096/fj.09-149328 10.1074/jbc.M800790200 10.1158/1078-0432.CCR-17-3717 10.1126/science.1230062 10.1038/nrc.2017.20 10.1126/science.aao0535 10.1007/s12035-015-9400-2 10.1007/s00401-018-1899-7 10.1126/science.aab0015 10.1038/s41388-018-0206-3 10.1126/science.aat6768 10.1086/374565 10.1210/jc.2014-1158 10.1111/cen.13513 10.1016/j.urolonc.2019.01.014 10.1038/s41467-018-04448-6 10.1002/jcp.25607 10.1158/1078-0432.CCR-12-1246 10.1111/cas.12806 10.1038/sj.emboj.7600196 10.1016/j.cell.2013.09.034 10.1101/gad.12.12.1769 10.1371/journal.pbio.2000016 10.1093/nar/29.14.3006 10.1038/s41568-018-0004-9 10.1038/nature14980 10.1126/science.279.5349.349 10.1016/j.cell.2014.02.009 10.1073/pnas.071043198 10.1038/s41576-019-0099-1 10.1016/S0378-1119(03)00739-X 10.1002/path.2530 10.1101/gr.242529.118 10.1101/gad.269498.115 10.1093/hmg/8.1.137 10.1093/jnci/93.15.1171 10.7554/eLife.07918 10.1093/jnci/djv1377 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2019 COPYRIGHT 2019 Nature Publishing Group 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2019 – notice: COPYRIGHT 2019 Nature Publishing Group – notice: 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TM 7TO 7U9 7X7 7XB 88A 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M7P MBDVC P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U RC3 7X8 5PM ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1038/s41388-019-0872-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) PML(ProQuest Medical Library) Research Library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic ProQuest SciTech Collection ProQuest Medical Library ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef Research Library Prep MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology |
| EISSN | 1476-5594 |
| EndPage | 6183 |
| ExternalDocumentID | oai_swepub_ki_se_478527 PMC6756069 A597078752 31285550 10_1038_s41388_019_0872_9 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- -Q- 0R~ 123 29N 2WC 36B 39C 4.4 406 53G 5RE 70F 7X7 8AO 8C1 8FE 8FH 8FI 8G5 8R4 8R5 AACDK AANZL AASML AATNV AAYZH ABAKF ABBRH ABDBE ABFSG ABJNI ABLJU ABRTQ ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACPRK ACRQY ACSTC ACZOJ ADBBV ADFRT AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFSHS AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN AZQEC BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI C6C CS3 DIK DNIVK DPUIP DU5 DWQXO E3Z EAP EBLON EBS EE. EIOEI EJD ESX F5P FDQFY FEDTE FERAY FIGPU FIZPM FSGXE FYUFA GUQSH HCIFZ HVGLF HZ~ IAO IHR INH INR ITC IWAJR JSO JZLTJ KQ8 L7B LGEZI LK8 LOTEE M1P M2O M7P N9A NADUK NQJWS NXXTH O9- OK1 P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT ROL SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TSG UKHRP WH7 88E 8FJ AAYXX ABUWG AFFHD CCPQU CITATION GNUQQ HMCUK PHGZM PHGZT PJZUB PPXIY PQGLB TUS .55 .GJ 3O- ABAWZ ABDBF ABEFU ACUHS AFFNX B0M BAWUL CAG CGR COF CUY CVF EAD EBC EBD ECM EIF EMB EMK EMOBN EPL NPM OVD RNS SV3 TEORI TR2 UDS X7M ZXP ~8M 3V. 7TM 7TO 7U9 7XB 88A 8FD 8FK FR3 H94 K9. MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U RC3 7X8 PUEGO 5PM ADTPV AOWAS D8T ZZAVC |
| ID | FETCH-LOGICAL-c641t-d534d91db28d90593916a3606ce9e1d3c47d333ffc31a8532364b52fb6ff79303 |
| IEDL.DBID | 8C1 |
| ISICitedReferencesCount | 337 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000482210100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0950-9232 1476-5594 |
| IngestDate | Tue Nov 25 03:36:18 EST 2025 Tue Nov 04 01:42:32 EST 2025 Fri Sep 05 06:01:50 EDT 2025 Mon Oct 06 18:22:34 EDT 2025 Tue Nov 11 10:15:28 EST 2025 Tue Nov 04 17:43:44 EST 2025 Mon Jul 21 04:15:22 EDT 2025 Sat Nov 29 04:02:44 EST 2025 Tue Nov 18 21:18:13 EST 2025 Mon Jul 21 06:08:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 34 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c641t-d534d91db28d90593916a3606ce9e1d3c47d333ffc31a8532364b52fb6ff79303 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://kipublications.ki.se/Default.aspx?queryparsed=id:141677504 |
| PMID | 31285550 |
| PQID | 2277419425 |
| PQPubID | 36330 |
| PageCount | 12 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_478527 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6756069 proquest_miscellaneous_2254510231 proquest_journals_2277419425 gale_infotracmisc_A597078752 gale_infotracacademiconefile_A597078752 pubmed_primary_31285550 crossref_primary_10_1038_s41388_019_0872_9 crossref_citationtrail_10_1038_s41388_019_0872_9 springer_journals_10_1038_s41388_019_0872_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-08-00 |
| PublicationDateYYYYMMDD | 2019-08-01 |
| PublicationDate_xml | – month: 08 year: 2019 text: 2019-08-00 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England – name: New York |
| PublicationTitle | Oncogene |
| PublicationTitleAbbrev | Oncogene |
| PublicationTitleAlternate | Oncogene |
| PublicationYear | 2019 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Zhang, Zheng, Lindvall, Hou, Ekedahl, Lewensohn (CR84) 2000; 60 Liu, Yuan, Xu (CR31) 2016; 7 Bell, Rube, Kreig, Mancini, Fouse, Nagarajan (CR55) 2015; 348 Mancini, Xavier-Magalhaes, Woods, Nguyen, Amen, Hayes (CR56) 2018; 34 Hu, Ni, Li, Yong, Yang, Zhang (CR9) 2017; 66 Takakura, Kyo, Sowa, Wang, Yatabe, Maida (CR42) 2001; 29 Fan, Liu, Fang, Ge, Ge, Jia (CR30) 2005; 11 Diplas, He, Brosnan-Cashman, Liu, Chen, Wang (CR76) 2018; 9 Gewin, Myers, Kiyono, Galloway (CR36) 2004; 18 Yuan, Cheng, Yu, Zheng, Sun, Sun (CR65) 2017; 8 Wang, Xie, Allan, Beach, Hannon (CR34) 1998; 12 Shay, Wright (CR5) 2019; 20 Wang, Liu, Liu, Meng, Yuan, Liu (CR89) 2015; 20 Brennan, Verhaak, McKenna, Campos, Noushmehr, Salama (CR96) 2016; 155 Dahlstrom, Liu, Yuan, Saft, Ghaderi, Wei (CR66) 2016; 95 Horikawa, Barrett (CR79) 2001; 93 Im, Yoon, Lee, Chung (CR8) 2017; 232 Seluanov, Gladyshev, Vijg, Gorbunova (CR2) 2018; 18 Vogelstein, Kinzler (CR1) 2015; 373 Castelo-Branco, Choufani, Mack, Gallagher, Zhang, Lipman (CR98) 2013; 14 Straat, Liu, Rahbar, Zhu, Liu, Wolmer-Solberg (CR48) 2009; 101 Levine, Cattoglio, Tjian (CR68) 2014; 157 Davis, Ricketts, Wang, Yang, Cherniack, Shen (CR74) 2014; 26 Chou, Hawkins, Barrett, Griffin, Dang (CR41) 2001; 108 Chiba, Lorbeer, Shain, McSwiggen, Schruf, Oh (CR63) 2017; 357 Zhao, Glasspool, Hoare, Bilsland, Szatmari, Keith (CR85) 2000; 2 Xu, Dwyer, Li, Duan, Liu (CR40) 2008; 283 Cassar, Li, Pinto, Nicholls, Bayne, Liu (CR35) 2008; 68 Li, Wu, Wang, Bi, Yang, Du (CR54) 2015; 6 CR53 Kim, Ludlow, Min, Robin, Stadler, Mender (CR22) 2016; 14 Lee, Leao, Komosa, Gallo, Zhang, Lipman (CR23) 2019; 129 Liu, Ding, Hao, Yang, Wu, Wang (CR19) 2016; 44 Li, Liu, Tollefsbol (CR38) 2010; 24 Takakura, Kyo, Kanaya, Hirano, Takeda, Yutsudo (CR27) 1999; 59 Park, Venteicher, Hong, Choi, Jun, Shkreli (CR17) 2009; 460 Zhang, Zheng, Hou, Lindvall, Li, Erlandsson (CR83) 2003; 72 Stern, Theodorescu, Vogelstein, Papadopoulos, Cech (CR57) 2015; 29 Casillas, Brotherton, Andrews, Ruppert, Tollefsbol (CR33) 2003; 316 Ge, Liu, Bjorkholm, Gruber, Xu (CR46) 2006; 26 Labgaa, Villacorta-Martin, D’Avola, Craig, von Felden, Martins-Filho (CR87) 2018; 37 Chen, Kost, Sulovari, Wong, Liang, Cao (CR67) 2019; 29 Wang, Li, Xu, Zhang, Liu, Tao (CR97) 2016; 53 Sung, Zheng, Li, Chen, Liu, Li (CR80) 2012; 44 Zeng, Wang, Li, Li, Bjorkholm, Jia (CR39) 2009; 218 Schilling, Penas, Janjetovic, Oliveira-Ferrer, Braig, Behrmann (CR70) 2013; 37 Bodnar, Ouellette, Frolkis, Holt, Chiu, Morin (CR7) 1998; 279 Cong, Wen, Bacchetti (CR21) 1999; 8 Hahn, Counter, Lundberg, Beijersbergen, Brooks, Weinberg (CR4) 1999; 400 Yu, Yuan, Sjoholm, Liu, Kong, Ekstrom (CR20) 2018; 434 Huang, Hodis, Xu, Kryukov, Chin, Garraway (CR51) 2013; 339 Bougel, Lhermitte, Gallagher, de Flaugergues, Janzer, Benhattar (CR91) 2013; 19 Wang, Xu, Sofiadis, Hoog, Vukojevic, Backdahl (CR26) 2014; 99 Hanahan, Weinberg (CR6) 2011; 144 Barthel, Wei, Tang, Martinez-Ledesma, Hu, Amin (CR49) 2017; 49 Xie, Liu, Wang, Bjornhagen, Hoog, Larsson (CR60) 2014; 5 Ding, Xi, Zhou, Wang, Cong (CR14) 2013; 27 Liu, Li, Li, Chen, Li, Hou (CR12) 2013; 32 Wong, Wright, Shay (CR28) 2014; 30 Ackermann, Cartolano, Hero, Welte, Kahlert, Roderwieser (CR72) 2018; 362 Zhao, Wang, Popova, Grigoryev, Zhu (CR69) 2009; 48 Zhang, Guo, Wang, Zhao, Ji, Cheng (CR13) 2017; 77 Ma, Liu, Lu, Yuan, Cheng, Kong (CR92) 2019; 37 Valentijn, Koster, Zwijnenburg, Hasselt, van Sluis, Volckmann (CR73) 2015; 47 Mitchell, Turajlic, Rowan, Nicol, Farmery, O’Brien (CR61) 2018; 173 Chang, Wang, Pickering, Huang, Tsai, Tsang (CR82) 2017; 39 Maida, Masutomi (CR18) 2015; 106 Yuan, Mu, Wang, Straat, Sofiadis, Guo (CR59) 2019; 38 Hurst, Platt, Knowles (CR88) 2014; 65 Koshiji, Kageyama, Pete, Horikawa, Barrett, Huang (CR37) 2004; 23 Saretzki (CR10) 2014; 20 Bellon, Nicot (CR47) 2008; 100 Hiyama, Hiyama, Yokoyama, Matsuura, Piatyszek, Shay (CR93) 1995; 1 Gomes, Ryder, Houck, Charter, Walker, Forsyth (CR3) 2011; 10 Nault, Datta, Imbeaud, Franconi, Mallet, Couchy (CR81) 2015; 47 Maryoung, Yue, Young, Newton, Barba, van Oers (CR64) 2017; 127 Xing, Liu, Liu, Murugan, Zhu, Zeiger (CR94) 2015; 32 Xu, Popov, Hou, Wang, Bjorkholm, Gruber (CR32) 2001; 98 CR95 Svahn, Juhlin, Paulsson, Fotouhi, Zedenius, Larsson (CR25) 2018; 88 Juratli, Stasik, Zolal, Schuster, Richter, Daubner (CR90) 2018; 24 Lassmann, Maida, Tomaru, Yasukawa, Ando, Kojima (CR15) 2015; 16 Liu, Liu, Fotouhi, Fan, Wang, Xia (CR24) 2017; 22 Bayard, Meunier, Peneau, Renault, Shinde, Nault (CR75) 2018; 9 Peifer, Hertwig, Roels, Dreidax, Gartlgruber, Menon (CR71) 2015; 526 Juratli, McCabe, Nayyar, Williams, Silverman, Tummala (CR78) 2018; 136 Li, Li, Liu, Liu, Liu, Straat (CR29) 2008; 260 Bell, Rube, Xavier-Magalhaes, Costa, Mancini, Song (CR52) 2016; 14 Drevytska, Nagibin, Gurianova, Kedlyan, Moibenko, Dosenko (CR16) 2014; 32 Sizemore, Pitarresi, Balakrishnan, Ostrowski (CR58) 2017; 17 Liu, Wang, Cao, Sofiadis, Dinets, Zedenius (CR62) 2014; 33 Paterlini-Brechot, Saigo, Murakami, Chami, Gozuacik, Mugnier (CR43) 2003; 22 Liu, Fang, Ge, Jalink, Kyo, Bjorkholm (CR45) 2007; 67 Dwight, Flynn, Amarasinghe, Benn, Lupat, Li (CR77) 2018; 25 Zhou, Mao, Zhou, Ding, Wang, Guo (CR44) 2014; 13 Horn, Figl, Rachakonda, Fischer, Sucker, Gast (CR50) 2013; 339 Masutomi, Possemato, Wong, Currier, Tothova, Manola (CR11) 2005; 102 Lin, Seger, Tsagkozis, Hesla, Ghaderi, Chen (CR86) 2018; 71 P Paterlini-Brechot (872_CR43) 2003; 22 S Horn (872_CR50) 2013; 339 I Labgaa (872_CR87) 2018; 37 Y Zhao (872_CR69) 2009; 48 T Liu (872_CR62) 2014; 33 Z Liu (872_CR12) 2013; 32 872_CR95 T Dwight (872_CR77) 2018; 25 K Zhang (872_CR13) 2017; 77 YS Cong (872_CR21) 1999; 8 W Li (872_CR29) 2008; 260 G Schilling (872_CR70) 2013; 37 F Svahn (872_CR25) 2018; 88 J Dahlstrom (872_CR66) 2016; 95 S Bougel (872_CR91) 2013; 19 Y Fan (872_CR30) 2005; 11 CW Brennan (872_CR96) 2016; 155 A Zhang (872_CR84) 2000; 60 G Saretzki (872_CR10) 2014; 20 JW Shay (872_CR5) 2019; 20 W Kim (872_CR22) 2016; 14 FP Barthel (872_CR49) 2017; 49 T Lassmann (872_CR15) 2015; 16 M Takakura (872_CR42) 2001; 29 WC Chou (872_CR41) 2001; 108 MS Wong (872_CR28) 2014; 30 X Yuan (872_CR65) 2017; 8 LJ Valentijn (872_CR73) 2015; 47 D Xu (872_CR32) 2001; 98 A Seluanov (872_CR2) 2018; 18 DD Lee (872_CR23) 2019; 129 K Wang (872_CR89) 2015; 20 A Mancini (872_CR56) 2018; 34 Z Ge (872_CR46) 2006; 26 TI Drevytska (872_CR16) 2014; 32 Y Lin (872_CR86) 2018; 71 RJ Bell (872_CR55) 2015; 348 E Im (872_CR8) 2017; 232 JQ Zhao (872_CR85) 2000; 2 T Liu (872_CR31) 2016; 7 N Wang (872_CR26) 2014; 99 BH Diplas (872_CR76) 2018; 9 M Peifer (872_CR71) 2015; 526 NM Gomes (872_CR3) 2011; 10 KP Chang (872_CR82) 2017; 39 E Hiyama (872_CR93) 1995; 1 M Levine (872_CR68) 2014; 157 C Hu (872_CR9) 2017; 66 L Cassar (872_CR35) 2008; 68 H Xie (872_CR60) 2014; 5 TA Juratli (872_CR90) 2018; 24 WC Hahn (872_CR4) 1999; 400 MA Casillas (872_CR33) 2003; 316 M Bellon (872_CR47) 2008; 100 K Chiba (872_CR63) 2017; 357 872_CR53 L Gewin (872_CR36) 2004; 18 P Castelo-Branco (872_CR98) 2013; 14 C Li (872_CR54) 2015; 6 D Xu (872_CR40) 2008; 283 RJ Bell (872_CR52) 2016; 14 CD Hurst (872_CR88) 2014; 65 JC Nault (872_CR81) 2015; 47 J Zhou (872_CR44) 2014; 13 J Zeng (872_CR39) 2009; 218 R Ma (872_CR92) 2019; 37 M Takakura (872_CR27) 1999; 59 M Koshiji (872_CR37) 2004; 23 K Straat (872_CR48) 2009; 101 X Chen (872_CR67) 2019; 29 A Zhang (872_CR83) 2003; 72 M Xing (872_CR94) 2015; 32 C Liu (872_CR45) 2007; 67 X Yuan (872_CR59) 2019; 38 WK Sung (872_CR80) 2012; 44 S Ackermann (872_CR72) 2018; 362 X Wang (872_CR97) 2016; 53 TA Juratli (872_CR78) 2018; 136 K Masutomi (872_CR11) 2005; 102 L Liu (872_CR24) 2017; 22 J Wang (872_CR34) 1998; 12 N Liu (872_CR19) 2016; 44 CF Davis (872_CR74) 2014; 26 Y Li (872_CR38) 2010; 24 JI Park (872_CR17) 2009; 460 L Maryoung (872_CR64) 2017; 127 FW Huang (872_CR51) 2013; 339 AG Bodnar (872_CR7) 1998; 279 D Ding (872_CR14) 2013; 27 TJ Mitchell (872_CR61) 2018; 173 J Yu (872_CR20) 2018; 434 I Horikawa (872_CR79) 2001; 93 B Vogelstein (872_CR1) 2015; 373 Q Bayard (872_CR75) 2018; 9 GM Sizemore (872_CR58) 2017; 17 D Hanahan (872_CR6) 2011; 144 Y Maida (872_CR18) 2015; 106 JL Stern (872_CR57) 2015; 29 |
| References_xml | – volume: 102 start-page: 8222 year: 2005 end-page: 7 ident: CR11 article-title: The telomerase reverse transcriptase regulates chromatin state and DNA damage responses publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0503095102 – volume: 20 start-page: 6386 year: 2014 end-page: 403 ident: CR10 article-title: Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress publication-title: Curr Pharm Des doi: 10.2174/1381612820666140630095606 – volume: 26 start-page: 319 year: 2014 end-page: 30 ident: CR74 article-title: The somatic genomic landscape of chromophobe renal cell carcinoma publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.07.014 – volume: 44 start-page: 8693 year: 2016 end-page: 703 ident: CR19 article-title: hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1 transcription factor publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw549 – volume: 77 start-page: 2534 year: 2017 end-page: 47 ident: CR13 article-title: WNT/beta-catenin directs self-renewal symmetric cell division of hTERT(high) prostate cancer stem cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-1887 – volume: 47 start-page: 1187 year: 2015 end-page: 93 ident: CR81 article-title: Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas publication-title: Nat Genet doi: 10.1038/ng.3389 – volume: 14 start-page: 534 year: 2013 end-page: 42 ident: CR98 article-title: Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70110-4 – volume: 144 start-page: 646 year: 2011 end-page: 74 ident: CR6 article-title: Hallmarks of cancer: the next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 32 start-page: 565 year: 2014 end-page: 70 ident: CR16 article-title: Silencing of TERT decreases levels of miR-1, miR-21, miR-29a and miR-208a in cardiomyocytes publication-title: Cell Biochem Funct doi: 10.1002/cbf.3051 – volume: 127 start-page: 982 year: 2017 end-page: 6 ident: CR64 article-title: Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations publication-title: J Clin Invest doi: 10.1172/JCI91161 – volume: 25 start-page: 1 year: 2018 end-page: 9 ident: CR77 article-title: TERT structural rearrangements in metastatic pheochromocytomas publication-title: Endocr Relat Cancer doi: 10.1530/ERC-17-0306 – volume: 9 year: 2018 ident: CR75 article-title: Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress publication-title: Nat Commun doi: 10.1038/s41467-018-07552-9 – volume: 460 start-page: 66 year: 2009 end-page: 72 ident: CR17 article-title: Telomerase modulates Wnt signalling by association with target gene chromatin publication-title: Nature doi: 10.1038/nature08137 – volume: 8 start-page: 23120 year: 2017 end-page: 9 ident: CR65 article-title: The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma publication-title: Oncotarget doi: 10.18632/oncotarget.15498 – volume: 173 start-page: 611 year: 2018 end-page: 23 e617 ident: CR61 article-title: Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal publication-title: Cell doi: 10.1016/j.cell.2018.02.020 – volume: 101 start-page: 488 year: 2009 end-page: 97 ident: CR48 article-title: Activation of telomerase by human cytomegalovirus publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp031 – volume: 32 start-page: 4203 year: 2013 end-page: 13 ident: CR12 article-title: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells publication-title: Oncogene doi: 10.1038/onc.2012.441 – volume: 13 start-page: 197 year: 2014 end-page: 200 ident: CR44 article-title: Endoplasmic reticulum stress activates telomerase publication-title: Aging Cell doi: 10.1111/acel.12161 – volume: 33 start-page: 4978 year: 2014 end-page: 84 ident: CR62 article-title: The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas publication-title: Oncogene doi: 10.1038/onc.2013.446 – volume: 44 start-page: 765 year: 2012 end-page: 9 ident: CR80 article-title: Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma publication-title: Nat Genet doi: 10.1038/ng.2295 – volume: 16 start-page: 1192 year: 2015 end-page: 208 ident: CR15 article-title: Telomerase reverse transcriptase regulates microRNAs publication-title: Int J Mol Sci doi: 10.3390/ijms16011192 – volume: 339 start-page: 957 year: 2013 end-page: 9 ident: CR51 article-title: Highly recurrent TERT promoter mutations in human melanoma publication-title: Science doi: 10.1126/science.1229259 – volume: 65 start-page: 367 year: 2014 end-page: 8 ident: CR88 article-title: Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine publication-title: Eur Urol doi: 10.1016/j.eururo.2013.08.057 – volume: 400 start-page: 464 year: 1999 end-page: 8 ident: CR4 article-title: Creation of human tumour cells with defined genetic elements publication-title: Nature doi: 10.1038/22780 – volume: 68 start-page: 9157 year: 2008 end-page: 66 ident: CR35 article-title: Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-1323 – volume: 47 start-page: 1411 year: 2015 end-page: 4 ident: CR73 article-title: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors publication-title: Nat Genet doi: 10.1038/ng.3438 – volume: 38 start-page: 965 year: 2019 end-page: 79 ident: CR59 article-title: GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression publication-title: Oncogene doi: 10.1038/s41388-018-0483-x – volume: 108 start-page: 1541 year: 2001 end-page: 7 ident: CR41 article-title: Arsenic inhibition of telomerase transcription leads to genetic instability publication-title: J Clin Invest doi: 10.1172/JCI14064 – volume: 95 start-page: 1825 year: 2016 end-page: 32 ident: CR66 article-title: TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations publication-title: Ann Hematol doi: 10.1007/s00277-016-2787-7 – volume: 66 start-page: 31 year: 2017 end-page: 42 ident: CR9 article-title: hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation publication-title: Gut doi: 10.1136/gutjnl-2015-309322 – volume: 7 start-page: E38 year: 2016 ident: CR31 article-title: Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: biological and clinical implications publication-title: Genes doi: 10.3390/genes7070038 – volume: 434 start-page: 33 year: 2018 end-page: 41 ident: CR20 article-title: Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma publication-title: Cancer Lett doi: 10.1016/j.canlet.2018.07.013 – volume: 5 start-page: 10048 year: 2014 end-page: 57 ident: CR60 article-title: TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma publication-title: Oncotarget doi: 10.18632/oncotarget.2491 – volume: 48 start-page: 963 year: 2009 end-page: 74 ident: CR69 article-title: Rearrangement of upstream sequences of the hTERT gene during cellular immortalization publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20698 – volume: 34 start-page: 513 year: 2018 end-page: 28 e518 ident: CR56 article-title: Disruption of the beta1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.08.003 – volume: 60 start-page: 6230 year: 2000 end-page: 5 ident: CR84 article-title: Frequent amplification of the telomerase reverse transcriptase gene in human tumors publication-title: Cancer Res – volume: 37 start-page: 280 year: 2013 end-page: 6 ident: CR70 article-title: Molecular characterization of chromosomal band 5p15.33: a recurrent breakpoint region in mantle cell lymphoma involving the TERT-CLPTM1L locus publication-title: Leuk Res doi: 10.1016/j.leukres.2012.10.009 – volume: 20 start-page: 263 year: 2015 end-page: 9 ident: CR89 article-title: TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer publication-title: Oncologist doi: 10.1634/theoncologist.2014-0391 – volume: 2 start-page: 531 year: 2000 end-page: 9 ident: CR85 article-title: Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3 publication-title: Neoplasia doi: 10.1038/sj.neo.7900114 – volume: 26 start-page: 230 year: 2006 end-page: 7 ident: CR46 article-title: Mitogen-activated protein kinase cascade-mediated histone H3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation publication-title: Mol Cell Biol doi: 10.1128/MCB.26.1.230-237.2006 – volume: 100 start-page: 98 year: 2008 end-page: 108 ident: CR47 article-title: Regulation of telomerase and telomeres: human tumor viruses take control publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djm269 – volume: 30 start-page: 430 year: 2014 end-page: 8 ident: CR28 article-title: Alternative splicing regulation of telomerase: a new paradigm? publication-title: Trends Genet doi: 10.1016/j.tig.2014.07.006 – volume: 22 start-page: 1178 year: 2017 end-page: 88 ident: CR24 article-title: TERT promoter hypermethylation in gastrointestinal cancer: a potential stool biomarker publication-title: Oncologist doi: 10.1634/theoncologist.2017-0064 – volume: 373 start-page: 1895 year: 2015 end-page: 8 ident: CR1 article-title: The path to cancer–three strikes and you’re out publication-title: N Engl J Med doi: 10.1056/NEJMp1508811 – volume: 71 start-page: 832 year: 2018 end-page: 9 ident: CR86 article-title: Telomerase promoter mutations and copy number alterations in solitary fibrous tumours publication-title: J Clin Pathol doi: 10.1136/jclinpath-2018-205132 – volume: 11 start-page: 4331 year: 2005 end-page: 7 ident: CR30 article-title: Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0099 – volume: 32 start-page: 2718 year: 2015 end-page: 26 ident: CR94 article-title: BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.5094 – volume: 18 start-page: 2269 year: 2004 end-page: 82 ident: CR36 article-title: Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex publication-title: Genes Dev doi: 10.1101/gad.1214704 – volume: 14 start-page: 315 year: 2016 end-page: 23 ident: CR52 article-title: Understanding TERT Promoter Mutations: A Common Path to Immortality publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-16-0003 – volume: 27 start-page: 4375 year: 2013 end-page: 83 ident: CR14 article-title: Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-kappaB-dependent transcription publication-title: FASEB J doi: 10.1096/fj.13-230904 – volume: 49 start-page: 349 year: 2017 end-page: 57 ident: CR49 article-title: Systematic analysis of telomere length and somatic alterations in 31 cancer types publication-title: Nat Genet doi: 10.1038/ng.3781 – volume: 1 start-page: 249 year: 1995 end-page: 55 ident: CR93 article-title: Correlating telomerase activity levels with human neuroblastoma outcomes publication-title: Nat Med doi: 10.1038/nm0395-249 – volume: 39 start-page: 1131 year: 2017 end-page: 7 ident: CR82 article-title: Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma publication-title: Head Neck doi: 10.1002/hed.24728 – volume: 67 start-page: 2626 year: 2007 end-page: 31 ident: CR45 article-title: The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-4126 – volume: 129 start-page: 223 year: 2019 end-page: 9 ident: CR23 article-title: DNA hypermethylation within TERT promoter upregulates TERT expression in cancer publication-title: J Clin Invest doi: 10.1172/JCI121303 – volume: 22 start-page: 3911 year: 2003 end-page: 6 ident: CR43 article-title: Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene publication-title: Oncogene doi: 10.1038/sj.onc.1206492 – volume: 6 start-page: 19542 year: 2015 end-page: 51 ident: CR54 article-title: The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer publication-title: Oncotarget doi: 10.18632/oncotarget.4295 – volume: 10 start-page: 761 year: 2011 end-page: 8 ident: CR3 article-title: Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination publication-title: Aging Cell doi: 10.1111/j.1474-9726.2011.00718.x – volume: 260 start-page: 28 year: 2008 end-page: 36 ident: CR29 article-title: Expression of the full-length telomerase reverse transcriptase (hTERT) transcript in both malignant and normal gastric tissues publication-title: Cancer Lett doi: 10.1016/j.canlet.2007.10.018 – volume: 24 start-page: 1442 year: 2010 end-page: 53 ident: CR38 article-title: Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression publication-title: FASEB J doi: 10.1096/fj.09-149328 – volume: 283 start-page: 23567 year: 2008 end-page: 80 ident: CR40 article-title: Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc publication-title: J Biol Chem doi: 10.1074/jbc.M800790200 – volume: 24 start-page: 5282 year: 2018 end-page: 91 ident: CR90 article-title: TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas: a pilot prospective study publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-3717 – volume: 339 start-page: 959 year: 2013 end-page: 61 ident: CR50 article-title: TERT promoter mutations in familial and sporadic melanoma publication-title: Science doi: 10.1126/science.1230062 – volume: 17 start-page: 337 year: 2017 end-page: 51 ident: CR58 article-title: The ETS family of oncogenic transcription factors in solid tumours publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.20 – volume: 357 start-page: 1416 year: 2017 end-page: 20 ident: CR63 article-title: Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism publication-title: Science doi: 10.1126/science.aao0535 – volume: 53 start-page: 2726 year: 2016 end-page: 32 ident: CR97 article-title: Association of telomerase reverse transcriptase promoter mutations with the prognosis of glioma patients: a meta-analysis publication-title: Mol Neurobiol doi: 10.1007/s12035-015-9400-2 – volume: 136 start-page: 779 year: 2018 end-page: 92 ident: CR78 article-title: DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome publication-title: Acta Neuropathol doi: 10.1007/s00401-018-1899-7 – volume: 348 start-page: 1036 year: 2015 end-page: 9 ident: CR55 article-title: The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer publication-title: Science doi: 10.1126/science.aab0015 – volume: 37 start-page: 3740 year: 2018 end-page: 52 ident: CR87 article-title: A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma publication-title: Oncogene doi: 10.1038/s41388-018-0206-3 – volume: 362 start-page: 1165 year: 2018 end-page: 70 ident: CR72 article-title: A mechanistic classification of clinical phenotypes in neuroblastoma publication-title: Science doi: 10.1126/science.aat6768 – volume: 72 start-page: 940 year: 2003 end-page: 8 ident: CR83 article-title: Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in Cri du chat syndrome publication-title: Am J Hum Genet doi: 10.1086/374565 – volume: 99 start-page: E1571 year: 2014 end-page: 9 ident: CR26 article-title: Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2014-1158 – volume: 88 start-page: 343 year: 2018 end-page: 5 ident: CR25 article-title: Telomerase reverse transcriptase promoter hypermethylation is associated with metastatic disease in abdominal paraganglioma publication-title: Clin Endocrinol doi: 10.1111/cen.13513 – ident: CR95 – volume: 37 start-page: 301 e301 year: 2019 end-page: 301 e310 ident: CR92 article-title: The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma publication-title: Urol Oncol doi: 10.1016/j.urolonc.2019.01.014 – volume: 9 year: 2018 ident: CR76 article-title: The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma publication-title: Nat Commun doi: 10.1038/s41467-018-04448-6 – volume: 232 start-page: 2083 year: 2017 end-page: 93 ident: CR8 article-title: Human telomerase reverse transcriptase (hTERT) positively regulates 26S proteasome activity publication-title: J Cell Physiol doi: 10.1002/jcp.25607 – volume: 19 start-page: 2216 year: 2013 end-page: 23 ident: CR91 article-title: Methylation of the hTERT promoter: a novel cancer biomarker for leptomeningeal metastasis detection in cerebrospinal fluids publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-1246 – ident: CR53 – volume: 106 start-page: 1486 year: 2015 end-page: 92 ident: CR18 article-title: Telomerase reverse transcriptase moonlights: therapeutic targets beyond telomerase publication-title: Cancer Sci doi: 10.1111/cas.12806 – volume: 23 start-page: 1949 year: 2004 end-page: 56 ident: CR37 article-title: HIF-1alpha induces cell cycle arrest by functionally counteracting Myc publication-title: Embo J doi: 10.1038/sj.emboj.7600196 – volume: 155 start-page: 462 year: 2016 end-page: 77 ident: CR96 article-title: The somatic genomic landscape of glioblastoma publication-title: Cell doi: 10.1016/j.cell.2013.09.034 – volume: 12 start-page: 1769 year: 1998 end-page: 74 ident: CR34 article-title: Myc activates telomerase publication-title: Genes Dev doi: 10.1101/gad.12.12.1769 – volume: 14 year: 2016 ident: CR22 article-title: Regulation of the human telomerase gene TERT by telomere position effect-over long distances (TPE-OLD): implications for aging and cancer publication-title: PLoS Biol doi: 10.1371/journal.pbio.2000016 – volume: 29 start-page: 3006 year: 2001 end-page: 11 ident: CR42 article-title: Telomerase activation by histone deacetylase inhibitor in normal cells publication-title: Nucleic Acids Res doi: 10.1093/nar/29.14.3006 – volume: 18 start-page: 433 year: 2018 end-page: 41 ident: CR2 article-title: Mechanisms of cancer resistance in long-lived mammals publication-title: Nat Rev Cancer doi: 10.1038/s41568-018-0004-9 – volume: 526 start-page: 700 year: 2015 end-page: 4 ident: CR71 article-title: Telomerase activation by genomic rearrangements in high-risk neuroblastoma publication-title: Nature doi: 10.1038/nature14980 – volume: 279 start-page: 349 year: 1998 end-page: 52 ident: CR7 article-title: Extension of life-span by introduction of telomerase into normal human cells publication-title: Science doi: 10.1126/science.279.5349.349 – volume: 157 start-page: 13 year: 2014 end-page: 25 ident: CR68 article-title: Looping back to leap forward: transcription enters a new era publication-title: Cell doi: 10.1016/j.cell.2014.02.009 – volume: 98 start-page: 3826 year: 2001 end-page: 31 ident: CR32 article-title: Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.071043198 – volume: 20 start-page: 299 year: 2019 end-page: 309 ident: CR5 article-title: Telomeres and telomerase: three decades of progress publication-title: Nat Rev Genet doi: 10.1038/s41576-019-0099-1 – volume: 316 start-page: 57 year: 2003 end-page: 65 ident: CR33 article-title: Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements publication-title: Gene doi: 10.1016/S0378-1119(03)00739-X – volume: 218 start-page: 419 year: 2009 end-page: 27 ident: CR39 article-title: FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1 publication-title: J Pathol doi: 10.1002/path.2530 – volume: 29 start-page: 819 year: 2019 end-page: 30 ident: CR67 article-title: A virome-wide clonal integration analysis platform for discovering cancer viral etiology publication-title: Genome Res doi: 10.1101/gr.242529.118 – volume: 59 start-page: 551 year: 1999 end-page: 7 ident: CR27 article-title: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells publication-title: Cancer Res – volume: 29 start-page: 2219 year: 2015 end-page: 24 ident: CR57 article-title: Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers publication-title: Genes Dev doi: 10.1101/gad.269498.115 – volume: 8 start-page: 137 year: 1999 end-page: 42 ident: CR21 article-title: The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter publication-title: Hum Mol Genet doi: 10.1093/hmg/8.1.137 – volume: 93 start-page: 1171 year: 2001 end-page: 3 ident: CR79 article-title: cis-Activation of the human telomerase gene (hTERT) by the hepatitis B virus genome publication-title: J Natl Cancer Inst doi: 10.1093/jnci/93.15.1171 – volume: 99 start-page: E1571 year: 2014 ident: 872_CR26 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2014-1158 – volume: 362 start-page: 1165 year: 2018 ident: 872_CR72 publication-title: Science doi: 10.1126/science.aat6768 – volume: 22 start-page: 1178 year: 2017 ident: 872_CR24 publication-title: Oncologist doi: 10.1634/theoncologist.2017-0064 – volume: 49 start-page: 349 year: 2017 ident: 872_CR49 publication-title: Nat Genet doi: 10.1038/ng.3781 – volume: 24 start-page: 1442 year: 2010 ident: 872_CR38 publication-title: FASEB J doi: 10.1096/fj.09-149328 – volume: 72 start-page: 940 year: 2003 ident: 872_CR83 publication-title: Am J Hum Genet doi: 10.1086/374565 – volume: 44 start-page: 8693 year: 2016 ident: 872_CR19 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw549 – volume: 155 start-page: 462 year: 2016 ident: 872_CR96 publication-title: Cell doi: 10.1016/j.cell.2013.09.034 – volume: 357 start-page: 1416 year: 2017 ident: 872_CR63 publication-title: Science doi: 10.1126/science.aao0535 – ident: 872_CR53 doi: 10.7554/eLife.07918 – volume: 348 start-page: 1036 year: 2015 ident: 872_CR55 publication-title: Science doi: 10.1126/science.aab0015 – volume: 8 start-page: 137 year: 1999 ident: 872_CR21 publication-title: Hum Mol Genet doi: 10.1093/hmg/8.1.137 – volume: 98 start-page: 3826 year: 2001 ident: 872_CR32 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.071043198 – volume: 8 start-page: 23120 year: 2017 ident: 872_CR65 publication-title: Oncotarget doi: 10.18632/oncotarget.15498 – volume: 37 start-page: 301 e301 year: 2019 ident: 872_CR92 publication-title: Urol Oncol doi: 10.1016/j.urolonc.2019.01.014 – volume: 48 start-page: 963 year: 2009 ident: 872_CR69 publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20698 – volume: 10 start-page: 761 year: 2011 ident: 872_CR3 publication-title: Aging Cell doi: 10.1111/j.1474-9726.2011.00718.x – volume: 39 start-page: 1131 year: 2017 ident: 872_CR82 publication-title: Head Neck doi: 10.1002/hed.24728 – volume: 24 start-page: 5282 year: 2018 ident: 872_CR90 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-3717 – volume: 16 start-page: 1192 year: 2015 ident: 872_CR15 publication-title: Int J Mol Sci doi: 10.3390/ijms16011192 – volume: 26 start-page: 319 year: 2014 ident: 872_CR74 publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.07.014 – volume: 27 start-page: 4375 year: 2013 ident: 872_CR14 publication-title: FASEB J doi: 10.1096/fj.13-230904 – volume: 14 year: 2016 ident: 872_CR22 publication-title: PLoS Biol doi: 10.1371/journal.pbio.2000016 – volume: 29 start-page: 3006 year: 2001 ident: 872_CR42 publication-title: Nucleic Acids Res doi: 10.1093/nar/29.14.3006 – volume: 23 start-page: 1949 year: 2004 ident: 872_CR37 publication-title: Embo J doi: 10.1038/sj.emboj.7600196 – volume: 29 start-page: 819 year: 2019 ident: 872_CR67 publication-title: Genome Res doi: 10.1101/gr.242529.118 – volume: 68 start-page: 9157 year: 2008 ident: 872_CR35 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-1323 – volume: 100 start-page: 98 year: 2008 ident: 872_CR47 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djm269 – volume: 20 start-page: 6386 year: 2014 ident: 872_CR10 publication-title: Curr Pharm Des doi: 10.2174/1381612820666140630095606 – volume: 136 start-page: 779 year: 2018 ident: 872_CR78 publication-title: Acta Neuropathol doi: 10.1007/s00401-018-1899-7 – volume: 2 start-page: 531 year: 2000 ident: 872_CR85 publication-title: Neoplasia doi: 10.1038/sj.neo.7900114 – volume: 19 start-page: 2216 year: 2013 ident: 872_CR91 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-1246 – volume: 32 start-page: 2718 year: 2015 ident: 872_CR94 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.5094 – volume: 12 start-page: 1769 year: 1998 ident: 872_CR34 publication-title: Genes Dev doi: 10.1101/gad.12.12.1769 – volume: 283 start-page: 23567 year: 2008 ident: 872_CR40 publication-title: J Biol Chem doi: 10.1074/jbc.M800790200 – volume: 5 start-page: 10048 year: 2014 ident: 872_CR60 publication-title: Oncotarget doi: 10.18632/oncotarget.2491 – volume: 37 start-page: 3740 year: 2018 ident: 872_CR87 publication-title: Oncogene doi: 10.1038/s41388-018-0206-3 – volume: 88 start-page: 343 year: 2018 ident: 872_CR25 publication-title: Clin Endocrinol doi: 10.1111/cen.13513 – volume: 13 start-page: 197 year: 2014 ident: 872_CR44 publication-title: Aging Cell doi: 10.1111/acel.12161 – volume: 232 start-page: 2083 year: 2017 ident: 872_CR8 publication-title: J Cell Physiol doi: 10.1002/jcp.25607 – volume: 26 start-page: 230 year: 2006 ident: 872_CR46 publication-title: Mol Cell Biol doi: 10.1128/MCB.26.1.230-237.2006 – volume: 129 start-page: 223 year: 2019 ident: 872_CR23 publication-title: J Clin Invest doi: 10.1172/JCI121303 – volume: 373 start-page: 1895 year: 2015 ident: 872_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMp1508811 – volume: 339 start-page: 957 year: 2013 ident: 872_CR51 publication-title: Science doi: 10.1126/science.1229259 – volume: 95 start-page: 1825 year: 2016 ident: 872_CR66 publication-title: Ann Hematol doi: 10.1007/s00277-016-2787-7 – volume: 9 year: 2018 ident: 872_CR75 publication-title: Nat Commun doi: 10.1038/s41467-018-07552-9 – volume: 44 start-page: 765 year: 2012 ident: 872_CR80 publication-title: Nat Genet doi: 10.1038/ng.2295 – volume: 6 start-page: 19542 year: 2015 ident: 872_CR54 publication-title: Oncotarget doi: 10.18632/oncotarget.4295 – volume: 460 start-page: 66 year: 2009 ident: 872_CR17 publication-title: Nature doi: 10.1038/nature08137 – volume: 20 start-page: 263 year: 2015 ident: 872_CR89 publication-title: Oncologist doi: 10.1634/theoncologist.2014-0391 – volume: 9 year: 2018 ident: 872_CR76 publication-title: Nat Commun doi: 10.1038/s41467-018-04448-6 – volume: 14 start-page: 534 year: 2013 ident: 872_CR98 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70110-4 – volume: 32 start-page: 4203 year: 2013 ident: 872_CR12 publication-title: Oncogene doi: 10.1038/onc.2012.441 – volume: 106 start-page: 1486 year: 2015 ident: 872_CR18 publication-title: Cancer Sci doi: 10.1111/cas.12806 – volume: 144 start-page: 646 year: 2011 ident: 872_CR6 publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 260 start-page: 28 year: 2008 ident: 872_CR29 publication-title: Cancer Lett doi: 10.1016/j.canlet.2007.10.018 – volume: 30 start-page: 430 year: 2014 ident: 872_CR28 publication-title: Trends Genet doi: 10.1016/j.tig.2014.07.006 – volume: 157 start-page: 13 year: 2014 ident: 872_CR68 publication-title: Cell doi: 10.1016/j.cell.2014.02.009 – volume: 17 start-page: 337 year: 2017 ident: 872_CR58 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.20 – volume: 102 start-page: 8222 year: 2005 ident: 872_CR11 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0503095102 – volume: 173 start-page: 611 year: 2018 ident: 872_CR61 publication-title: Cell doi: 10.1016/j.cell.2018.02.020 – volume: 59 start-page: 551 year: 1999 ident: 872_CR27 publication-title: Cancer Res – volume: 29 start-page: 2219 year: 2015 ident: 872_CR57 publication-title: Genes Dev doi: 10.1101/gad.269498.115 – volume: 434 start-page: 33 year: 2018 ident: 872_CR20 publication-title: Cancer Lett doi: 10.1016/j.canlet.2018.07.013 – volume: 93 start-page: 1171 year: 2001 ident: 872_CR79 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/93.15.1171 – volume: 400 start-page: 464 year: 1999 ident: 872_CR4 publication-title: Nature doi: 10.1038/22780 – volume: 14 start-page: 315 year: 2016 ident: 872_CR52 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-16-0003 – volume: 25 start-page: 1 year: 2018 ident: 872_CR77 publication-title: Endocr Relat Cancer doi: 10.1530/ERC-17-0306 – volume: 77 start-page: 2534 year: 2017 ident: 872_CR13 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-1887 – volume: 32 start-page: 565 year: 2014 ident: 872_CR16 publication-title: Cell Biochem Funct doi: 10.1002/cbf.3051 – ident: 872_CR95 doi: 10.1093/jnci/djv1377 – volume: 34 start-page: 513 year: 2018 ident: 872_CR56 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.08.003 – volume: 218 start-page: 419 year: 2009 ident: 872_CR39 publication-title: J Pathol doi: 10.1002/path.2530 – volume: 38 start-page: 965 year: 2019 ident: 872_CR59 publication-title: Oncogene doi: 10.1038/s41388-018-0483-x – volume: 279 start-page: 349 year: 1998 ident: 872_CR7 publication-title: Science doi: 10.1126/science.279.5349.349 – volume: 127 start-page: 982 year: 2017 ident: 872_CR64 publication-title: J Clin Invest doi: 10.1172/JCI91161 – volume: 33 start-page: 4978 year: 2014 ident: 872_CR62 publication-title: Oncogene doi: 10.1038/onc.2013.446 – volume: 60 start-page: 6230 year: 2000 ident: 872_CR84 publication-title: Cancer Res – volume: 1 start-page: 249 year: 1995 ident: 872_CR93 publication-title: Nat Med doi: 10.1038/nm0395-249 – volume: 339 start-page: 959 year: 2013 ident: 872_CR50 publication-title: Science doi: 10.1126/science.1230062 – volume: 37 start-page: 280 year: 2013 ident: 872_CR70 publication-title: Leuk Res doi: 10.1016/j.leukres.2012.10.009 – volume: 20 start-page: 299 year: 2019 ident: 872_CR5 publication-title: Nat Rev Genet doi: 10.1038/s41576-019-0099-1 – volume: 18 start-page: 433 year: 2018 ident: 872_CR2 publication-title: Nat Rev Cancer doi: 10.1038/s41568-018-0004-9 – volume: 47 start-page: 1187 year: 2015 ident: 872_CR81 publication-title: Nat Genet doi: 10.1038/ng.3389 – volume: 22 start-page: 3911 year: 2003 ident: 872_CR43 publication-title: Oncogene doi: 10.1038/sj.onc.1206492 – volume: 66 start-page: 31 year: 2017 ident: 872_CR9 publication-title: Gut doi: 10.1136/gutjnl-2015-309322 – volume: 108 start-page: 1541 year: 2001 ident: 872_CR41 publication-title: J Clin Invest doi: 10.1172/JCI14064 – volume: 47 start-page: 1411 year: 2015 ident: 872_CR73 publication-title: Nat Genet doi: 10.1038/ng.3438 – volume: 11 start-page: 4331 year: 2005 ident: 872_CR30 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0099 – volume: 7 start-page: E38 year: 2016 ident: 872_CR31 publication-title: Genes doi: 10.3390/genes7070038 – volume: 316 start-page: 57 year: 2003 ident: 872_CR33 publication-title: Gene doi: 10.1016/S0378-1119(03)00739-X – volume: 101 start-page: 488 year: 2009 ident: 872_CR48 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp031 – volume: 526 start-page: 700 year: 2015 ident: 872_CR71 publication-title: Nature doi: 10.1038/nature14980 – volume: 18 start-page: 2269 year: 2004 ident: 872_CR36 publication-title: Genes Dev doi: 10.1101/gad.1214704 – volume: 67 start-page: 2626 year: 2007 ident: 872_CR45 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-4126 – volume: 53 start-page: 2726 year: 2016 ident: 872_CR97 publication-title: Mol Neurobiol doi: 10.1007/s12035-015-9400-2 – volume: 71 start-page: 832 year: 2018 ident: 872_CR86 publication-title: J Clin Pathol doi: 10.1136/jclinpath-2018-205132 – volume: 65 start-page: 367 year: 2014 ident: 872_CR88 publication-title: Eur Urol doi: 10.1016/j.eururo.2013.08.057 |
| SSID | ssj0007902 |
| Score | 2.6875226 |
| SecondaryResourceType | review_article |
| Snippet | Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby... |
| SourceID | swepub pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6172 |
| SubjectTerms | 631/67/395 631/67/68 Apoptosis Cancer Care and treatment Cell Biology Cell differentiation Cell Transformation, Neoplastic - genetics Derepression Development and progression Diagnosis Disease Progression Gene Expression Regulation, Neoplastic Gene regulation Gene silencing Genetic transcription Genetic transformation Genomics Human Genetics Humans Hyperactivity Immortalization Internal Medicine Medicine Medicine & Public Health Mutation Neoplasms - genetics Neoplasms - metabolism Neoplasms - pathology Next-generation sequencing Oncology Post-transcription Promoter Regions, Genetic Review Review Article RNA-directed DNA polymerase Senescence Telomerase Telomerase - genetics Telomerase - metabolism Telomerase reverse transcriptase Telomere - genetics Telomere - metabolism Telomere Homeostasis - genetics Telomere Shortening - genetics Telomeres Therapeutic applications Transcription activation Transcription factors Transcription, Genetic Tumorigenesis |
| Title | Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players |
| URI | https://link.springer.com/article/10.1038/s41388-019-0872-9 https://www.ncbi.nlm.nih.gov/pubmed/31285550 https://www.proquest.com/docview/2277419425 https://www.proquest.com/docview/2254510231 https://pubmed.ncbi.nlm.nih.gov/PMC6756069 http://kipublications.ki.se/Default.aspx?queryparsed=id:141677504 |
| Volume | 38 |
| WOSCitedRecordID | wos000482210100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: M7P dateStart: 19970101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: 7X7 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: BENPR dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: 8C1 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library (ProQuest) customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: M2O dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xu7wuPJZXYKmMhEACRZvYSe1wQUu1Kw60VGiReosc2xEVJSlNF4kLv52ZPFrSQy9cora2W7v-PP7GngfAy0yIoVLW-TmFf4wyGfnKaOMHiQ6ltchobR1n9pOcTNRslkzbA7eqNavsZGItqG1p6Iz8lHMkKqhx8_j98qdPWaPodrVNoXEARyEPIlqYarQ18ZCNzSGyiMBHIsO7W02hTisU3orMuBI_UJL7SW9f2pXO_2xPu6aTm_vTnVij9f50cfd_R3YP7rTMlJ01ULoP11xxDDeaXJW_j-HWqEsNdww3x-2N_AP4M3bkOzyvflSM_NFWC_KbYkgrGblMNAe-rMwZ0uZLtqadsZNTTBeWrd2ipHOxqq2PSgGbF6xOHcgMQXL1jpULy5q8QHUb1ATYcqFJWXgIXy_OL0cf_Tang2-GUbj2bSwim4Q248omlE4Q6akWqEUZl7jQChNJK4TIcyNCjVSC4ttnMc-zYZ6jKAnEIzgsysI9ARaScZ6SKo61jpzOM4oVyDOT5ToORKY9CLoZTU0b8JzybizS-uJdqLQBQYogSAkEaeLBm02TZRPtY1_l1wSTlCQBfi8ivHFowN5RTK30DHU1JGAy5h6c9GribJl-cQeMtJUgVbpFhQcvNsXUkqziCldeUR3kvxR7I_TgcYPLTbcFEo8Y1U8PZA-xmwoUV7xfUsy_1fHFUYfECcHxve2wve3Wnn_jVQP_3g-0H33HVy6NcK64fLp_tM_gNm9WJS7OEzhcr67cc7hufq3n1WoAB3Im66ca1Gt9AEcfzifTL_huzD_TU07_AhjaW9I |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwEB4ty2O58CivwAJG4iGBok3spE6QEFotrHa1bcWhSL2ZxHZERUlL0wXthZ_Eb2QmryU99LYHblVsp449T3vmG4DnqRD9KDLWzQj-MUhl4EY60a4XJ740Bi1aU-LMDuRoFE0m8act-NPkwlBYZSMTS0Ft5prOyPc4R0MFPW4evl_8cKlqFN2uNiU0KrI4sWe_0GUr3h1_wP19wfnhx_HBkVtXFXB1P_BXrglFYGLfpDwyMRW0QwMpEWjHaxtb3wgdSCOEyDIt_ASVGSGspyHP0n6WITF7At97CS6jHJcUQiYnrYPnySrGEa0Wz0XDiTe3qCLaK1BZRBQ2FrteJLkbd_Tgujb4Rx2uh2q297Vr2KalPjy8-b-t5C24UVvebL9ilduwZfMeXK1qcZ71YOegKX3Xg2vDOuLgDvweWsqNnhbfC0b5dssZ5YUxNJsZpYRUB9psnjF0C8ZsRZq_kcMsyQ1b2dmczv2Kuj86PWyas7I0ItPEcsu3bD4zrKp7VI5BT4ctZgk5Q3fh84WsyT3Yzue5fQDMp-DDSEZhmCSBTbKUsBB5qtMsCT2RJg54DQUpXQO6U12RmSoDC0SkKqJTSHSKiE7FDrxuhywqNJNNnV8RWSqSdPhe5OAqYQNnR5hhah99UTQwZcgd2O30xN3S3eaGEFUtIQt1ToUOPGubaSRF_eV2fkp90L4nbBHfgfsVH7TTFmhYheheOyA7HNJ2INz0bks-_Vrip6OPjBuC3_em4aXzaW1YjZcVu3X-oH70DX9ZFeBecflw89c-hZ2j8XCgBsejk0dwnVcSAQXDLmyvlqf2MVzRP1fTYvmklC0Mvlw0C_4FrCWx0A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aGwxeuJRbYICRuEigqImdNAkSQmNbxbStqqYh7S0ktiMqSlKaDrQXfhi_jnPiJCN96NseeKtiO3Xsc_mOfS4AL1IhBmGotJ1R-kcvDTw7lIm0nShxA6UQ0aoqz-xhMBqFp6fReA3-NLEw5FbZyMRKUKtC0hl5n3MEKmhxc7-f1W4R493hh9kPmypI0U1rU07DkMiBPv-F5lv5fn8X9_ol58O9k51Pdl1hwJYDz13YyheeilyV8lBFVNwOwVIiENNLHWlXCekFSgiRZVK4CSo2yrae-jxLB1mGhO0IfO8V2AgQZCB3bXzcG42PWz0QGI9HxDCOjTCKN3eqIuyXqDpCciKLbCcMuB11tOKybvhHOS47bra3t0uZTivtOLz1P6_rbbhZY3K2bZjoDqzpvAfXTJXO8x5c32mK4vVg86j2RbgLv480RU1Pyu8lo0i8-ZQixhgCakbBIuaomxUZQ4PhhC0IEzQSmiW5Ygs9LehEsKz7oznEJjmriiYyScw4f8eKqWKmIlI1Bm0gNpsmZCbdg8-Xsib3YT0vcv0QmEtuiWEQ-n6SeDrJUsqSyFOZZonviDSxwGmoKZZ1qneqODKNK5cDEcaGAGMkwJgIMI4seNMOmZk8J6s6vyYSjUkG4nuRt00oB86OsonF22ilIvQMfG7BVqcn7pbsNjdEGdeys4wvKNKC520zjSR_wFwXZ9QHkT9lHXEteGB4op22QMjlo-FtQdDhlrYDZVTvtuSTr1VmdbSecUPw-942fHUxrRWr8cqwXucP6kff8JeOPdwrHjxa_bXPYBM5Lz7cHx08hhvcCAeUEVuwvpif6SdwVf5cTMr501rQMPhy2Tz4FxDqu_E |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanisms+underlying+the+activation+of+TERT+transcription+and+telomerase+activity+in+human+cancer%3A+old+actors+and+new+players&rft.jtitle=Oncogene&rft.au=Yuan%2C+X&rft.au=Larsson%2C+C&rft.au=Xu%2C+D&rft.date=2019-08-01&rft.issn=0950-9232&rft.volume=38&rft.issue=34&rft.spage=6172&rft_id=info:doi/10.1038%2Fs41388-019-0872-9&rft.externalDocID=oai_swepub_ki_se_478527 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon |